Related Experiment Video
Updated: Sep 24, 2025
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Safety evaluation of secukinumab in pediatric patients with plaque psoriasis
Klaudia Bardowska1, Piotr K Krajewski1, Kinga Tyczyńska1
1Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wrocław, Poland.
Insights
Secukinumab shows promise for treating pediatric psoriasis, with available data indicating a favorable safety profile and sustained effectiveness in improving quality of life for children with moderate to severe plaque psoriasis.
Area of Science:
- Pediatric Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis (Ps) is a chronic inflammatory skin disease impacting children's quality of life and associated with comorbidities.
- Secukinumab, an IL-17A inhibitor, is approved for pediatric psoriasis but lacks extensive safety data in this population.
Purpose of the Study:
- To review available data on secukinumab's safety and efficacy in pediatric plaque psoriasis.
- To highlight adverse effects associated with secukinumab treatment in children.
Main Methods:
- Extensive literature review of secukinumab in pediatric psoriasis.
- Analysis of safety and efficacy data from clinical trials.
Main Results:
- Limited long-term safety data exists, but current evidence suggests a favorable safety profile with no serious unexpected adverse events.
- Sustained efficacy demonstrated by PASI 75 achievement and improved quality of life.
Conclusions:
- Secukinumab is a potentially promising treatment for moderate to severe pediatric psoriasis.
- The therapy exhibits a favorable safety profile and sustained clinical benefits in children.
Introduction:
Psoriasis (Ps) is a common chronic, recurrent, immune-mediated, inflammatory skin disease affecting up to 2% of children. It has a well-established impact on patients' quality of life. Moreover, patients with psoriasis exhibit a higher prevalence of comorbidities, including hypertension, diabetes, and inflammatory bowel disease. Secukinumab is a fully human monoclonal IL-17A antibody, which has been approved for use in children with psoriasis. Nevertheless, there are very little data on the safety of this therapy in the pediatric population.
Areas Covered:
The aim of this article was to perform an extensive review of available data concerning secukinumab safety and efficiency in the pediatric population used for the treatment of plaque psoriasis. Moreover, special attention was paid to underline the adverse effects of secukinumab.
Expert Opinion:
Although there is very little evidence on the long-term safety of secukinumab use in the pediatric population, this therapy may be a promising modality in children with moderate to severe psoriasis. The available data confirm its favorable safety profile with no serious adverse events and unexpected events. Moreover, the clinical trials revealed sustained efficiency with respect to reaching PASI 75 and decreasing impact of the disease on quality of life.
